Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Shi-Ming Tu

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Medicine, College of Medicine
DivisionHematology Oncology
Address CAMPUS
4301 W. Markham
Mail Slot # 508
Little Rock AR 72205
ORCID ORCID Icon0000-0003-0015-2111 Additional info
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    S2200     (TU, SHI-MING)Sep 6, 2023 - Sep 5, 2033
    SouthWest Oncology Group
    S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Tabet GC, Zheng L, Hosseini H, Ward J, Pisters L, Campbell MT, Tu SM, Czerniak B, Guo CC. Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases. Hum Pathol. 2024 Nov; 153:105673. PMID: 39461379.
      View in: PubMed
    2. Ercanbrack CW, Kwok AS, Chauhan MZ, Tu SM, Uwaydat S. Early Optical Coherence Tomography Signs of Erdafitinib-Induced Retinopathy. Cureus. 2024 Aug; 16(8):e66968. PMID: 39280433.
      View in: PubMed
    3. Jackson JC, Sanchez D, Johns AC, Campbell MT, Aydin AM, Gokden N, Maraboyina S, Muesse JL, Ward JF, Pisters LL, Zacharias NM, Guo CC, Tu SM. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med. 2024 Jun 12; 13(12). PMID: 38929965.
      View in: PubMed
    4. Tu SM, Trikannad AK, Vellanki S, Hussain M, Malik N, Singh SR, Jillella A, Obulareddy S, Malapati S, Bhatti SA, Arnaoutakis K, Atiq OT. Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care. Cancers (Basel). 2024 Mar 14; 16(6). PMID: 38539487.
      View in: PubMed
    5. Tu SM, Chen JZ, Singh SR, Maraboyina S, Gokden N, Hsu PC, Langford T. Stem Cell Theory of Cancer: Clinical Implications for Cellular Metabolism and Anti-Cancer Metabolomics. Cancers (Basel). 2024 Jan 31; 16(3). PMID: 38339375.
      View in: PubMed
    6. Tu SM, Chen JZ, Singh SR, Aydin AM, Gokden N, Tam NNC, Leung YK, Langford T, Ho SM. Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care. Cancers (Basel). 2023 Nov 22; 15(23). PMID: 38067237.
      View in: PubMed
    7. Tu SM, Aydin AM, Maraboyina S, Chen Z, Singh S, Gokden N, Langford T. Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy. Cancers (Basel). 2023 Nov 13; 15(22). PMID: 38001645.
      View in: PubMed
    8. Tu SM, Aydin AM, Maraboyina S, Chen Z, Singh S, Gokden N, Langford T. Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care. Cancers (Basel). 2023 Apr 27; 15(9). PMID: 37173982.
      View in: PubMed
    9. Tu SM, Singh SR, Arnaoutakis K, Malapati S, Bhatti SA, Joon AY, Atiq OT, Pisters LL. Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers (Basel). 2022 Jul 09; 14(14). PMID: 35884406.
      View in: PubMed
    10. Tu SM, Moran C, Norton W, Zacharias NM. Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. Semin Diagn Pathol. 2023 Jan; 40(1):63-68. PMID: 35729019.
      View in: PubMed
    11. Tu SM, Guo CC, Chow DS, Zacharias NM. Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. Cancers (Basel). 2022 Mar 18; 14(6). PMID: 35326699.
      View in: PubMed
    12. Tu SM, Pisters LL. Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267646.
      View in: PubMed
    13. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5). PMID: 35267435.
      View in: PubMed
    14. Tu SM, Estecio MR, Lin SH, Zacharias NM. Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy? Cancers (Basel). 2022 Jan 27; 14(3). PMID: 35158923.
      View in: PubMed
    15. Hwang MJ, Hamza A, Zhang M, Tu SM, Pisters LL, Czerniak B, Guo CC. Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol. 2022 01 01; 46(1):11-17. PMID: 34334690.
      View in: PubMed
    16. Tu SM, Zhang M, Wood CG, Pisters LL. Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers (Basel). 2021 Aug 09; 13(16). PMID: 34439162.
      View in: PubMed
    17. Tu SM. Stem Cell Theory of Cancer: Implications of a Viral Etiology in Certain Malignancies. Cancers (Basel). 2021 Jun 01; 13(11). PMID: 34205851.
      View in: PubMed
    18. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358. PMID: 33824525.
      View in: PubMed
    19. Tu SM. The Cancer Genome: Paradigm or Paradox? Cancers (Basel). 2021 Feb 08; 13(4). PMID: 33567511.
      View in: PubMed
    20. Tu SM, Pisters LL. Curing Cancer: Lessons from a Prototype. Cancers (Basel). 2021 Feb 07; 13(4). PMID: 33562202.
      View in: PubMed
    21. Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14; 12(12). PMID: 33327406.
      View in: PubMed
    22. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306. PMID: 33279304.
      View in: PubMed
    23. Umbreit EC, McIntosh AG, Suk-Ouichai C, Segarra LA, Holland LC, Fellman BM, Williams SB, Thomas AZ, Tu SM, Pettaway CA, Pisters LL, Ward JF, Wood CG, Karam JA. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020 11 15; 126(22):4878-4885. PMID: 32940929.
      View in: PubMed
    24. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673. PMID: 32453443.
      View in: PubMed
    25. Siddiqui BA, Zhang M, Pisters LL, Tu SM. Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S56-S65. PMID: 32055486.
      View in: PubMed
    26. Ho L, Pisters L, Tu SM. Rapidly enlarging abdominal mass in a patient with recurrent germ cell tumor. Clin Case Rep. 2019 Nov; 7(11):2285-2286. PMID: 31788307.
      View in: PubMed
    27. Chahoud J, Zhang M, Pisters LL, Lin SC, Lin SH, Tu SM. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018 10; 16(5):325-327. PMID: 29807831.
      View in: PubMed
    28. Chahoud J, Zhang M, Shah A, Lin SH, Pisters LL, Tu SM. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol. 2018 05; 30(3):181-188. PMID: 29538040.
      View in: PubMed
    29. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589. PMID: 28730293.
      View in: PubMed
    30. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143.
      View in: PubMed
    31. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785.
      View in: PubMed
    32. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8. PMID: 25347368.
      View in: PubMed
    33. Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, Tu SM. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer. 2014 Aug; 12(4):e147-50. PMID: 24674785.
      View in: PubMed
    34. Som A, Xiao L, Zhu R, Guo CC, Xiao L, Rao P, Efstathiou E, Matin A, Tu SM. Clinically atypical seminomas with yolk sac tumor features. Can J Urol. 2013 Aug; 20(4):6860-7. PMID: 23930614.
      View in: PubMed
    35. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96. PMID: 21290244.
      View in: PubMed
    36. Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501. PMID: 20822932.
      View in: PubMed
    37. Contreras AL, Punar M, Tamboli P, Tu SM, Pisters L, Moran C, Czerniak BA, Guo CC. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol. 2010 Jun; 41(6):832-7. PMID: 20153508.
      View in: PubMed
    38. Tu SM. Origin of cancers. Clinical perspectives and implications of a stem-cell theory of cancer. Cancer Treat Res. 2010; 154:v-239. PMID: 20645140.
      View in: PubMed
    39. Guo CC, Punar M, Contreras AL, Tu SM, Pisters L, Tamboli P, Czerniak B. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009 Aug; 33(8):1173-8. PMID: 19561445.
      View in: PubMed
    40. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80. PMID: 19402048.
      View in: PubMed
    41. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar 15; 115(6):1310-7. PMID: 19156903.
      View in: PubMed
    42. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8. PMID: 17948916.
      View in: PubMed
    43. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec; 70(6):1173-8. PMID: 18158041.
      View in: PubMed
    44. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol. 2007 Apr; 177(4):1330-4; discussion 1334. PMID: 17382725.
      View in: PubMed
    45. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan 15; 109(2):198-204. PMID: 17171704.
      View in: PubMed
    46. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan; 177(1):131-8. PMID: 17162023.
      View in: PubMed
    47. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006 Oct 01; 107(7):1503-10. PMID: 16944534.
      View in: PubMed
    48. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 01; 107(7):1483-90. PMID: 16944541.
      View in: PubMed
    49. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002 Aug; 3(8):508-13. PMID: 12147437.
      View in: PubMed
    50. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7. PMID: 12173328.
      View in: PubMed
    Tu's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (117) concept(s)
    _
    Co-Authors Expand Description
    See all (17) people
    _
    Similar People Expand Description
    See all (35) people
    _
    Same Department Expand Description
    Search Department